SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Abgenix, Inc. (ABGX)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: John McCarthy who wrote (531)11/8/2005 8:25:10 PM
From: John McCarthy   of 590
 
"better than Avastin"

caution - because CONTEXT is everything ......

If I say Mickey Mantle is better than Bud Harrelson
I had better have STATS on both and then
compare

Batting Avg
RBI's
HR
Runs
and so on to *prove* my point .....

which is a long way to ask this question:

At which SPECIFIC Avastin trial or trials is
Roger Perlmutter using as a basis for his statement.

It would seen to me that if he cannot back up his
statement then AMGN stockholders and their lawyers
are gonna have a field day.

Again this is from the article ....

<<<<<<<<<<<<<<<
AMG 706 is being studied in patients with gastrointestinal tumors who have become resistant to Gleevec, a cancer drug sold by Novartis AG (NOVN.VX: Quote, Profile, Research) .

Perlmutter said the drug is "better than Avastin," because it inhibits all of the tumor growth receptors, rather than just the one that Avastin blocks
<<<<<<<<<<<<<<<

I am getting lost here because I thought he was talking
about Gleevec and then apparently jumps back (???) to
compare Avastin and P.

In closing, (and please fix my attitude) I don't recall
a company spokesperson being so TONEWISE (1) direct (2) in your face when talking about (a) their drug and (b) the FDA.

Maybe I am just too old to keep up ...

regards,
John
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext